|
1
|
Louis DN: Molecular pathology of malignant
gliomas. Annu Rev Pathol. 1:97–117. 2006. View Article : Google Scholar
|
|
2
|
Stupp R, Hegi ME, Mason WP, van den Bent
MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B,
Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ,
Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M,
Lacombe D, Cairncross JG and Mirimanoff RO; European Organisation
for Research and Treatment of Cancer Brain Tumour and Radiation
Oncology Groups; National Cancer Institute of Canada Clinical
Trials Group: National Cancer Institute of Canada Clinical Trials
Group. Effects of radiotherapy with concomitant and adjuvant
temozolomide versus radiotherapy alone on survival in glioblastoma
in a randomised phase III study: 5-year analysis of the EORTC-NCIC
trial. Lancet Oncol. 10:459–466. 2009.
|
|
3
|
Nagai Y, Kojima T, Muro Y, Hachiya T,
Nishizawa Y, Wakabayashi T and Hagiwara M: Identification of a
novel nuclear speckle-type protein, SPOP. FEBS Lett. 418:23–26.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hernández-Muñoz I, Lund AH, van der Stoop
P, Boutsma E, Muijrers I, Verhoeven E, Nusinow DA, Panning B,
Marahrens Y and van Lohuizen M: Stable X chromosome inactivation
involves the PRC1 Polycomb complex and requires histone MACROH2A1
and the CULLIN3/SPOP ubiquitin E3 ligase. Proc Natl Acad Sci USA.
102:7635–7640. 2005.PubMed/NCBI
|
|
5
|
Kwon JE, La M, Oh KH, Oh YM, Kim GR, Seol
JH, Baek SH, Chiba T, Tanaka K, Bang OS, Joe CO and Chung CH: BTB
domain-containing speckle-type POZ protein (SPOP) serves as an
adaptor of Daxx for ubiquitination by Cul3-based ubiquitin ligase.
J Biol Chem. 281:12664–12672. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kan Z, Jaiswal BS, Stinson J, Janakiraman
V, Bhatt D, Stern HM, Yue P, Haverty PM, Bourgon R, Zheng J,
Moorhead M, Chaudhuri S, Tomsho LP, Peters BA, Pujara K, Cordes S,
Davis DP, Carlton VE, Yuan W, Li L, Wang W, Eigenbrot C, Kaminker
JS, Eberhard DA, Waring P, Schuster SC, Modrusan Z, Zhang Z, Stokoe
D, de Sauvage FJ, Faham M and Seshagiri S: Diverse somatic mutation
patterns and pathway alterations in human cancers. Nature.
466:869–873. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Berger MF, Lawrence MS, Demichelis F,
Drier Y, Cibulskis K, Sivachenko AY, Sboner A, Esgueva R, Pflueger
D, Sougnez C, Onofrio R, Carter SL, Park K, Habegger L, Ambrogio L,
Fennell T, Parkin M, Saksena G, Voet D, Ramos AH, Pugh TJ,
Wilkinson J, Fisher S, Winckler W, Mahan S, Ardlie K, Baldwin J,
Simons JW, Kitabayashi N, MacDonald TY, Kantoff PW, Chin L, Gabriel
SB, Gerstein MB, Golub TR, Meyerson M, Tewari A, Lander ES, Getz G,
Rubin MA and Garraway LA: The genomic complexity of primary human
prostate cancer. Nature. 470:214–220. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Barbieri CE, Baca SC, Lawrence MS,
Demichelis F, Blattner M, Theurillat JP, White TA, Stojanov P, Van
Allen E, Stransky N, Nickerson E, Chae SS, Boysen G, Auclair D,
Onofrio RC, Park K, Kitabayashi N, MacDonald TY, Sheikh K, Vuong T,
Guiducci C, Cibulskis K, Sivachenko A, Carter SL, Saksena G, Voet
D, Hussain WM, Ramos AH, Winckler W, Redman MC, Ardlie K, Tewari
AK, Mosquera JM, Rupp N, Wild PJ, Moch H, Morrissey C, Nelson PS,
Kantoff PW, Gabriel SB, Golub TR, Meyerson M, Lander ES, Getz G,
Rubin MA and Garraway LA: Exome sequencing identifies recurrent
SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet.
44:685–689. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Le Gallo M, O’Hara AJ, Rudd ML, Urick ME,
Hansen NF, O’Neil NJ, Price JC, Zhang S, England BM and Godwin AK:
Exome sequencing of serous endometrial tumors identifies recurrent
somatic mutations in chromatin-remodeling and ubiquitin ligase
complex genes. Nat Genet. 44:1310–1315. 2012.PubMed/NCBI
|
|
10
|
Ande SR, Chen J and Maddika S: The
ubiquitin pathway: an emerging drug target in cancer therapy. Eur J
Pharmacol. 625:199–205. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Li C, Ao J, Fu J, Lee DF, Xu J, Lonard D
and O’Malley BW: Tumor-suppressor role for the SPOP ubiquitin
ligase in signal-dependent proteolysis of the oncogenic
co-activator SRC-3/AIB1. Oncogene. 30:4350–4364. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nakayama KI and Nakayama K: Ubiquitin
ligases: cell-cycle control and cancer. Nat Rev Cancer. 6:369–381.
2006. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bode AM and Dong Z: Post-translational
modification of p53 in tumorigenesis. Nat Rev Cancer. 4:793–805.
2004. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kim MS, Je EM, Oh JE, Yoo NJ and Lee SH:
Mutational and expressional analyses of SPOP, a candidate tumor
suppressor gene, in prostate, gastric and colorectal cancers.
APMIS. 121:626–633. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Dahmane N, Sánchez P, Gitton Y, Palma V,
Sun T, Beyna M, Weiner H and Ruiz i Altaba A: The Sonic
Hedgehog-Gli pathway regulates dorsal brain growth and
tumorigenesis. Development. 128:5201–5212. 2001.PubMed/NCBI
|
|
16
|
Liu J, Ghanim M, Xue L, Brown CD, Iossifov
I, Angeletti C, Hua S, Nègre N, Ludwig M, Stricker T, Al-Ahmadie
HA, Tretiakova M, Camp RL, Perera-Alberto M, Rimm DL, Xu T,
Rzhetsky A and White KP: Analysis of Drosophila segmentation
network identifies a JNK pathway factor overexpressed in kidney
cancer. Science. 323:1218–1222. 2009. View Article : Google Scholar
|
|
17
|
Liu Y, Melin BS, Rajaraman P, Wang Z,
Linet M, Shete S, Amos CI, Lau CC, Scheurer ME, Tsavachidis S,
Armstrong GN, Houlston RS, Hosking FJ, Claus EB, Barnholtz-Sloan J,
Lai R, Il’yasova D, Schildkraut J, Sadetzki S, Johansen C,
Bernstein JL, Olson SH, Jenkins RB, LaChance D, Vick NA, Wrensch M,
Davis F, McCarthy BJ, Andersson U, Thompson PA, Chanock S and Bondy
ML; Gliogene Consortium. Insight in glioma susceptibility through
an analysis of 6p22.3, 12p13.33-12.1, 17q22-23.2 and 18q23 SNP
genotypes in familial and non-familial glioma. Hum Genet.
131:1507–1517. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Louis DN, Ohgaki H, Wiestler OD and
Cavenee WK: WHO Classifcation of Tumours of the Central Nervous
System. 4th edition. IARC Press; Lyon: 2007
|
|
19
|
Van Meir EG, Hadjipanayis CG, Norden AD,
Shu HK, Wen PY and Olson JJ: Exciting new advances in
neuro-oncology: the avenue to a cure for malignant glioma. CA
Cancer J Clin. 60:166–193. 2010.PubMed/NCBI
|
|
20
|
Mrugala MM: Advances and challenges in the
treatment of glioblastoma: a clinician’s perspective. Discov Med.
15:221–230. 2013.PubMed/NCBI
|
|
21
|
Zhang Q, Zhang L, Wang B, Ou CY, Chien CT
and Jiang J: A hedgehog-induced BTB protein modulates hedgehog
signaling by degrading Ci/Gli transcription factor. Dev Cell.
10:719–729. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhuang M, Calabrese MF, Liu J, Waddell MB,
Nourse A, Hammel M, Miller DJ, Walden H, Duda DM, Seyedin SN,
Hoggard T, Harper JW, White KP and Schulman BA: Structures of
SPOP-substrate complexes: insights into molecular architectures of
BTB-Cul3 ubiquitin ligases. Mol Cell. 36:39–50. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bunce MW, Boronenkov IV and Anderson RA:
Coordinated activation of the nuclear ubiquitin ligase Cul3-SPOP by
the generation of phosphatidylinositol 5-phosphate. J Biol Chem.
283:8678–8686. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chen MH, Wilson CW, Li YJ, Law KK, Lu CS,
Gacayan R, Zhang X, Hui CC and Chuang PT: Cilium-independent
regulation of Gli protein function by Sufu in Hedgehog signaling is
evolutionarily conserved. Genes Dev. 23:1910–1928. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Claiborn KC, Sachdeva MM, Cannon CE, Groff
DN, Singer JD and Stoffers DA: Pcif1 modulates Pdx1 protein
stability and pancreatic β cell function and survival in mice. J
Clin Invest. 120:3713–3721. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hoeller D and Dikic I: Targeting the
ubiquitin system in cancer therapy. Nature. 458:438–444. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Cohen P and Tcherpakov M: Will the
ubiquitin system furnish as many drug targets as protein kinases.
Cell. 143:686–693. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Torres-Arzayus MI, Font de Mora J, Yuan J,
Vazquez F, Bronson R, Rue M, Sellers WR and Brown M: High tumor
incidence and activation of the PI3K/AKT pathway in transgenic mice
define AIB1 as an oncogene. Cancer Cell. 6:263–274. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Byun B, Tak H and Joe CO: BTB/POZ domain
of speckle-type POZ protein (SPOP) confers proapoptotic function in
HeLa cells. Biofactors. 31:165–169. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Li G, Ci W, Karmakar S, Chen K, Dhar R,
Fan Z, Guo Z, Zhang J, Ke Y, Wang L, Zhuang M, Hu S, Li X, Zhou L,
Li X, Calabrese MF, Watson ER, Prasad SM, Rinker-Schaeffer C,
Eggener SE, Stricker T, Tian Y, Schulman BA, Liu J and White KP:
SPOP promotes tumorigenesis by acting as a key regulatory hub in
kidney cancer. Cancer Cell. 25:455–468. 2014. View Article : Google Scholar : PubMed/NCBI
|
